Early Post-marketing Study of Eliquis (Apixaban)

Trial Profile

Early Post-marketing Study of Eliquis (Apixaban)

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 19 Aug 2016

At a glance

  • Drugs Apixaban (Primary)
  • Indications Pulmonary embolism; Stroke; Thromboembolism; Venous thromboembolism
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 15 Aug 2016 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
    • 16 Apr 2015 Planned number of patients changed from 50 to 25, according to to ClinicalTrials.gov record.
    • 16 Apr 2015 Planned End Date changed from 1 Jun 2016 to 1 Nov 2016, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top